A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/31/2002	CA2445250A1 Three-step conversion of protected taxane ester to paclitaxel
10/31/2002	CA2445236A1 Piperazino-derivatives and their use as pde4 inhibitor
10/31/2002	CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002	CA2445202A1 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002	CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	CA2445179A1 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002	CA2445160A1 Coumarin derivatives to be used as anticoagulants
10/31/2002	CA2445114A1 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
10/31/2002	CA2445087A1 Hop extracts and use thereof in the production of a medicament having estrogenic properties
10/31/2002	CA2445071A1 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002	CA2445042A1 Two-step conversion of protected taxane ester to paclitaxel
10/31/2002	CA2444907A1 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5
10/31/2002	CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002	CA2444883A1 Microprojection array having a beneficial agent containing coating
10/31/2002	CA2444745A1 Method of preventing or treating breast, prostate and/or cervical cancer with n,n-dimethylglycine
10/31/2002	CA2444675A1 Secreted proteins
10/31/2002	CA2444599A1 Melanocortin receptor ligands
10/31/2002	CA2444592A1 Novel azoles having an insecticidal action
10/31/2002	CA2444570A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002	CA2444563A1 Tissue fibrosis inhibitors
10/31/2002	CA2444381A1 Novel compounds
10/31/2002	CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	CA2444347A1 Method for treating gout and binding uric acid
10/31/2002	CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002	CA2444219A1 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002	CA2444214A1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/31/2002	CA2444095A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002	CA2444036A1 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002	CA2444028A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002	CA2443946A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002	CA2443944A1 Agent for prophylaxis or treatment of inflammatory diseases in mucosa of oral cavity and the like
10/31/2002	CA2443939A1 Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base
10/31/2002	CA2443937A1 Prostanoids augment ocular drug penetration
10/31/2002	CA2443936A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002	CA2443935A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002	CA2443605A1 Process for purifying 6-methoxy omeprazole
10/31/2002	CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	CA2443560A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
10/31/2002	CA2443556A1 Novel 3-c(o)r substituted 10-cyclohexylbenzoyl pyrrolobenzodiazepines; tocolytic oxytocin receptor antagonists
10/31/2002	CA2443518A1 Controlled release particles
10/31/2002	CA2442994A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
10/31/2002	CA2442591A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002	CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/31/2002	CA2441785A1 Fast disintegrating meloxicam tablet
10/31/2002	CA2441540A1 Replikin peptides and uses thereof
10/31/2002	CA2439960A1 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists)
10/31/2002	CA2439959A1 A method for the preparation of oxazolidinones
10/31/2002	CA2436273A1 Method for producing an active ingredient concentrate, and an active ingredient concentrate
10/31/2002	CA2436240A1 Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
10/31/2002	CA2429351A1 A novel human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/30/2002	EP1253142A1 Compounds exhibiting thrombopoietin receptor agonism
10/30/2002	EP1253141A1 Substituted carbazoles as tubulin polymerization inhibitors and their use for the treatment of cancer
10/30/2002	EP1253139A2 Multioligoanilinated fullerenes
10/30/2002	EP1252897A1 Drugs for gene therapy
10/30/2002	EP1252893A1 Medicine containing anemonin as effective component for treating aseptic inflammation
10/30/2002	EP1252892A1 Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor
10/30/2002	EP1252891A1 Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
10/30/2002	EP1252890A1 Remedies or preventives for digestive diseases containing diaminotrifluoromethylpyridine derivatives
10/30/2002	EP1252889A1 Remedies or preventives for pulmonary insufficiency containing diaminotrifluoromethylpyridine derivatives
10/30/2002	EP1252888A1 Biologically active labdane or labdene derivatives from Cistus
10/30/2002	EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002	EP1252882A1 Process to increase the threshold tolerance of the sensitive skin
10/30/2002	EP1252824A2 Method for improving bone mineralization
10/30/2002	EP1252820A1 Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs
10/30/2002	EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002	EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002	EP1252322A2 Herpes virus strains for gene therapy
10/30/2002	EP1252308A2 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
10/30/2002	EP1252307A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
10/30/2002	EP1252306A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
10/30/2002	EP1252194A1 Heparin with average molecular mass
10/30/2002	EP1252182A1 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
10/30/2002	EP1252175A1 Antisense modulation of survivin expression
10/30/2002	EP1252171A1 Method for preparing functionalised beta-(1,3)-glucan derivatives
10/30/2002	EP1252170A2 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
10/30/2002	EP1252165A1 Isoxazolo pyrimidinones and the use thereof
10/30/2002	EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002	EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002	EP1252162A1 Alpha v integrin receptor antagonists
10/30/2002	EP1252161A1 Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor
10/30/2002	EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002	EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002	EP1252156A1 Blockade of voltage dependent sodium channels
10/30/2002	EP1252155A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
10/30/2002	EP1252154A1 Heterocyclic amide derivatives
10/30/2002	EP1252153A1 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
10/30/2002	EP1252152A1 Urea compounds as inhibitors for vla-4
10/30/2002	EP1252150A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
10/30/2002	EP1252146A1 Amide compounds for inhibiting protein kinases
10/30/2002	EP1252145A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/30/2002	EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002	EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002	EP1252142A1 Indole derivatives as mcp-1 receptor antagonists
10/30/2002	EP1252141A1 Tosylproline analogs as thymidylate synthase inhibitors
10/30/2002	EP1252138A2 A new process for the preparation of latanoprost
10/30/2002	EP1252137A1 Palatable arginine compounds and uses thereof for cardiovascular health
10/30/2002	EP1252133A2 Pharmaceutical compounds
10/30/2002	EP1251874A1 Stabilised pharmaceutical compositions and process for their preparation comprising an antibiotic and an expectorant
10/30/2002	EP1251871A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
10/30/2002	EP1251870A2 Novel use

1 ... 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 5684 5685 ... 7860